223 related articles for article (PubMed ID: 24409060)
1. Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer.
Harder J; Müller MJ; Fuchs M; Gumpp V; Schmitt-Graeff A; Fischer R; Frank M; Opitz O; Hasskarl J
World J Gastroenterol; 2013 Dec; 19(48):9334-42. PubMed ID: 24409060
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.
Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E
Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078
[TBL] [Abstract][Full Text] [Related]
3. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
[TBL] [Abstract][Full Text] [Related]
4. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts.
Tran Cao HS; Zhang Q; Sada YH; Chai C; Curley SA; Massarweh NN
Cancer; 2018 Jan; 124(1):74-83. PubMed ID: 28841223
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is a marker that predicts presence of invasion in papillary biliary tumors.
Sasaki M; Sato Y
Hum Pathol; 2017 Apr; 62():152-159. PubMed ID: 28089541
[TBL] [Abstract][Full Text] [Related]
6. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
[No Abstract] [Full Text] [Related]
7. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
[TBL] [Abstract][Full Text] [Related]
8. Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.
Li T; Qin LX; Zhou J; Sun HC; Qiu SJ; Ye QH; Wang L; Tang ZY; Fan J
Liver Int; 2014 Jul; 34(6):953-60. PubMed ID: 24134199
[TBL] [Abstract][Full Text] [Related]
9. Hepatobiliary cancers, version 2.2014.
Benson AB; D'Angelica MI; Abrams TA; Are C; Bloomston PM; Chang DT; Clary BM; Covey AM; Ensminger WD; Iyer R; Kelley RK; Linehan D; Malafa MP; Meranze SG; Park JO; Pawlik T; Posey JA; Scaife C; Schefter T; Sigurdson ER; Tian GG; Vauthey JN; Venook AP; Yen Y; Zhu AX; Hoffmann KG; McMillian NR; Sundar H
J Natl Compr Canc Netw; 2014 Aug; 12(8):1152-82. PubMed ID: 25099447
[TBL] [Abstract][Full Text] [Related]
10. CD98 is a promising prognostic biomarker in biliary tract cancer.
Kaira K; Sunose Y; Oriuchi N; Kanai Y; Takeyoshi I
Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):654-7. PubMed ID: 25475870
[TBL] [Abstract][Full Text] [Related]
11. [Gallbladder and bile duct carcinoma. Biology and pathology].
Tannapfel A; Wittekind C
Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
[TBL] [Abstract][Full Text] [Related]
12. Gamma-synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma.
Takemura Y; Ojima H; Oshima G; Shinoda M; Hasegawa Y; Kitago M; Yagi H; Abe Y; Hori S; Fujii-Nishimura Y; Kubota N; Masuda Y; Hibi T; Sakamoto M; Kitagawa Y
Cancer Med; 2021 Aug; 10(16):5599-5613. PubMed ID: 34245137
[TBL] [Abstract][Full Text] [Related]
13. R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer.
Matull WR; Dhar DK; Ayaru L; Sandanayake NS; Chapman MH; Dias A; Bridgewater J; Webster GJ; Bong JJ; Davidson BR; Pereira SP
Liver Int; 2011 Jan; 31(1):99-107. PubMed ID: 20846273
[TBL] [Abstract][Full Text] [Related]
14. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
15. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.
Riener MO; Vogetseder A; Pestalozzi BC; Clavien PA; Probst-Hensch N; Kristiansen G; Jochum W
Hum Pathol; 2010 Nov; 41(11):1558-65. PubMed ID: 20621328
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
17. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
McNamara MG; Lopes A; Wasan H; Malka D; Goldstein D; Shannon J; Okusaka T; Knox JJ; Wagner AD; André T; Cunningham D; Moehler M; Jensen LH; Koeberle D; Bekaii-Saab T; Bridgewater J; Valle JW
J Hepatol; 2020 Nov; 73(5):1109-1117. PubMed ID: 32446715
[TBL] [Abstract][Full Text] [Related]
18. Landscape of distant metastasis mode and current chemotherapy efficacy of the advanced biliary tract cancer in the United States, 2010-2016.
Wang J; Bo X; Nan L; Wang CC; Gao Z; Suo T; Ni X; Liu H; Lu P; Wang Y; Liu H
Cancer Med; 2020 Feb; 9(4):1335-1348. PubMed ID: 31876990
[TBL] [Abstract][Full Text] [Related]
19. Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC).
Ji JH; Song HN; Kim RB; Oh SY; Lim HY; Park JO; Park SH; Kim MJ; Lee SI; Ryou SH; Hwang IG; Jang JS; Kim HJ; Choi JY; Kang JH
Jpn J Clin Oncol; 2015 Mar; 45(3):256-60. PubMed ID: 25628352
[TBL] [Abstract][Full Text] [Related]
20. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study.
Kato A; Shimizu H; Ohtsuka M; Yoshidome H; Yoshitomi H; Furukawa K; Takeuchi D; Takayashiki T; Kimura F; Miyazaki M
Ann Surg Oncol; 2013 Jan; 20(1):318-24. PubMed ID: 23149849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
